The purpose of this study is to evaluate the efficacy of Seroquel XR in schizophrenia patients with acute worsening symptoms. Consequently, to assess whether the study drug is safe and acceptable on the daily dose basis, orally given, up to 600 mg once a day for 42 days.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
28
600mg Extended release tablet, oral, once daily
Research Site
Bangkok, Thailand
Research Site
Chiang Mai, Thailand
Research Site
Songkhla, Thailand
Change in Positive and Negative Syndrome Scale (PANSS) Total Score
Change in Positive and Negative Syndrome Scale Total Score from Day 1 (baseline) to Day 42 (final visit) or withdrawal. Minimum value of total PANSS is 30 , Maximum is 210. Minimum value considered better is score decreased from baseline at least 30%.
Time frame: From Day 1 (baseline) to Day 42
Change in Clinical Global Impression - Severity of Illness (CGI-S) Score
Clinical Global Impression - Severity of Illness. Maximum possible value is 7 (worst outcome), the minimum is 1 (best outcome). Values are considered better outcome: decrease from baseline \> 1 score.
Time frame: From Day 1 (Baseline) to Day 42
Clinical Global Impression - Severity of Illness (CGI-S) Score
Clinical Global Impression - Severity of Illness. Maximum possible value is 7 (worst outcome), the minimum is 1 (best outcome). Values are considered better outcome: decrease from baseline \> 1 score.
Time frame: Day 14
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.